JP2021515599A5 - - Google Patents

Info

Publication number
JP2021515599A5
JP2021515599A5 JP2020571344A JP2020571344A JP2021515599A5 JP 2021515599 A5 JP2021515599 A5 JP 2021515599A5 JP 2020571344 A JP2020571344 A JP 2020571344A JP 2020571344 A JP2020571344 A JP 2020571344A JP 2021515599 A5 JP2021515599 A5 JP 2021515599A5
Authority
JP
Japan
Prior art keywords
seq
cytokine
prodrug according
polypeptide
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020571344A
Other languages
English (en)
Japanese (ja)
Other versions
JP7515412B2 (ja
JP2021515599A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/021654 external-priority patent/WO2019173832A2/en
Publication of JP2021515599A publication Critical patent/JP2021515599A/ja
Publication of JP2021515599A5 publication Critical patent/JP2021515599A5/ja
Priority to JP2024106766A priority Critical patent/JP7820448B2/ja
Application granted granted Critical
Publication of JP7515412B2 publication Critical patent/JP7515412B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020571344A 2018-03-09 2019-03-11 新規のサイトカインプロドラッグ Active JP7515412B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024106766A JP7820448B2 (ja) 2018-03-09 2024-07-02 新規のサイトカインプロドラッグ

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201862640969P 2018-03-09 2018-03-09
US62/640,969 2018-03-09
US201862643104P 2018-03-14 2018-03-14
US62/643,104 2018-03-14
US201862644384P 2018-03-17 2018-03-17
US62/644,384 2018-03-17
US201862644577P 2018-03-18 2018-03-18
US62/644,577 2018-03-18
US201862680707P 2018-06-05 2018-06-05
US62/680,707 2018-06-05
US201962801649P 2019-02-06 2019-02-06
US62/801,649 2019-02-06
PCT/US2019/021654 WO2019173832A2 (en) 2018-03-09 2019-03-11 Novel cytokine prodrugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024106766A Division JP7820448B2 (ja) 2018-03-09 2024-07-02 新規のサイトカインプロドラッグ

Publications (3)

Publication Number Publication Date
JP2021515599A JP2021515599A (ja) 2021-06-24
JP2021515599A5 true JP2021515599A5 (enExample) 2022-03-23
JP7515412B2 JP7515412B2 (ja) 2024-07-12

Family

ID=66175477

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020571344A Active JP7515412B2 (ja) 2018-03-09 2019-03-11 新規のサイトカインプロドラッグ
JP2024106766A Active JP7820448B2 (ja) 2018-03-09 2024-07-02 新規のサイトカインプロドラッグ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024106766A Active JP7820448B2 (ja) 2018-03-09 2024-07-02 新規のサイトカインプロドラッグ

Country Status (6)

Country Link
US (2) US20210260163A1 (enExample)
EP (1) EP3762406A2 (enExample)
JP (2) JP7515412B2 (enExample)
CN (1) CN113166220A (enExample)
CA (1) CA3115461A1 (enExample)
WO (1) WO2019173832A2 (enExample)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7626577B2 (ja) 2016-11-28 2025-02-07 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
BR112019008727A2 (pt) 2016-11-28 2019-07-16 Chugai Seiyaku Kabushiki Kaisha domínio de ligação ao antígeno, e polipeptídeo incluindo seção de transporte
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
KR20240141853A (ko) 2017-08-03 2024-09-27 신톡스, 인크. 자가면역 질환의 치료를 위한 사이토카인 접합체
EP4029877B1 (en) 2017-08-03 2024-01-17 Amgen Inc. Interleukin-21 muteins and methods of treatment
JP7482630B2 (ja) 2017-11-28 2024-05-14 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
TWI880235B (zh) 2017-11-28 2025-04-11 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
JP7513605B2 (ja) * 2018-07-18 2024-07-09 アスクジーン・ファーマ・インコーポレイテッド 新規な抗体ならびにそれを調製および使用するための方法
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CA3098930A1 (en) 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
EP3854805A4 (en) * 2018-09-21 2022-08-24 Innovent Biologics (Suzhou) Co., Ltd. NOVEL INTERLEUKIN 2 AND ITS USE
US20220002370A1 (en) * 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
EP3923974A4 (en) 2019-02-06 2023-02-08 Synthorx, Inc. IL-2 CONJUGATES AND METHODS OF USE THEREOF
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
US20220227837A1 (en) * 2019-05-24 2022-07-21 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
CA3141626A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
WO2021016599A1 (en) * 2019-07-25 2021-01-28 Trutino Biosciences Inc Il-2 cytokine prodrugs comprising a cleavable linker
WO2021024020A1 (en) * 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CA3148505A1 (en) * 2019-08-12 2021-02-18 AskGene Pharma, Inc. Novel il-2 fusion molecules
US12234271B2 (en) 2019-09-10 2025-02-25 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases
AU2020353235A1 (en) * 2019-09-28 2022-03-31 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
MX2022005666A (es) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
MX2022007202A (es) * 2019-12-13 2022-10-07 Cugene Inc Fármacos bioactivables a base de citocinas y metodos de uso de los mismos.
WO2021127487A2 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
AU2020412716A1 (en) 2019-12-23 2022-08-18 Sanofi Methods of preparing N6-((2-azidoethoxy)carbonyl)lysine
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
CA3165927A1 (en) * 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
BR112022013993A2 (pt) * 2020-01-15 2022-10-11 Trutino Biosciences Inc Profármacos de citocina compreendendo um ligante clivável
EP4093875A4 (en) * 2020-01-20 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Ligand-binding fusion proteins
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
JP7773991B2 (ja) * 2020-03-23 2025-11-20 ザイムワークス ビーシー インコーポレイテッド マスクされたｉｌ１２融合タンパク質及びその使用方法
EP4126246A4 (en) * 2020-04-01 2024-05-15 Xilio Development, Inc. MASKED IL-15 CYTOKINE AND THEIR DECOMPOSITION PRODUCTS
JP7771076B2 (ja) * 2020-04-01 2025-11-17 エクシリオ デベロップメント， インコーポレイテッド マスクされたｉｌ－１２サイトカイン及びその切断産物
TW202204388A (zh) * 2020-04-01 2022-02-01 美商艾希利歐發展股份有限公司 經遮蔽之il-2細胞激素及其裂解產物
WO2021207669A1 (en) 2020-04-10 2021-10-14 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
EP4143220A4 (en) * 2020-04-30 2024-05-29 Immune Targeting Inc. COMPOSITION OF ACTIVATABLE IL2 AND METHODS OF USE
IL298136A (en) 2020-05-13 2023-01-01 Bonum Therapeutics Inc Preparations of protein complexes and methods of using them
AU2021310520A1 (en) * 2020-07-14 2023-02-16 Pfizer Inc. Recombinant vaccinia virus
IL301027A (en) * 2020-09-04 2023-05-01 Shandong Simcere Biopharmaceutical Co Ltd Mutant AI 2 and its application
JP2023540629A (ja) * 2020-09-16 2023-09-25 ベイジーン リミテッド インターロイキン１５構築物及び使用方法
CN117500518A (zh) * 2020-09-18 2024-02-02 地方独立行政法人 宫城县立医院机构 Il-2突变蛋白及包含其的药物
TW202406932A (zh) * 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
CN117500824A (zh) * 2021-02-01 2024-02-02 奥美药业有限公司 包含IL-10或TGF-β激动剂多肽的嵌合分子
CN112553256B (zh) * 2021-02-20 2021-06-22 北京百普赛斯生物科技股份有限公司 Il-2受体复合物及其制备方法与应用
BR112023018735A2 (pt) 2021-03-16 2023-11-28 Cytomx Therapeutics Inc Construtos de citocinas ativáveis mascarados e composições e métodos relacionados
MX2023012489A (es) * 2021-04-22 2023-11-22 Guangdong Fapon Biopharma Inc Polipeptido de fusion biespecifico multifuncional.
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
CN118043079A (zh) * 2021-06-17 2024-05-14 格治(香港)生物科技有限公司 免疫缀合物分子及其相关方法和组合物
WO2023281480A1 (en) * 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Conjugates of checkpoint inhibitors with il-2, and uses thereof
US20230201365A1 (en) * 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
AU2022306974A1 (en) 2021-07-09 2024-01-04 Bright Peak Therapeutics Ag Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
WO2023004004A1 (en) * 2021-07-23 2023-01-26 Merck Sharp & Dohme Llc Il-2 muteins for treating cancer or infection
AR127343A1 (es) * 2021-10-13 2024-01-31 Cytomx Therapeutics Inc Construcciones de citoquinas activables triméricas y composiciones y métodos relacionados
CN118510795A (zh) * 2022-01-07 2024-08-16 苏州克睿基因生物科技有限公司 新型白介素-2多肽
JP2025505434A (ja) * 2022-01-31 2025-02-26 オーフス ユニバーシテット タンパク質構造変化に基づくバイオ医薬プロドラッグプラットホーム
WO2023151661A1 (zh) * 2022-02-11 2023-08-17 江苏恒瑞医药股份有限公司 免疫缀合物及其用途
AU2023226005A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
JP7843362B2 (ja) * 2022-03-03 2026-04-09 ハイナン シンセア ファーマスーティカル カンパニー、リミテッド ＩＬ２変異体－抗体Ｆｃブロック融合タンパク質の医薬組成物及びその使用
CN114853909A (zh) * 2022-05-13 2022-08-05 南京吉盛澳玛生物医药有限公司 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途
WO2023222886A1 (en) * 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins
US20240254223A1 (en) * 2022-09-02 2024-08-01 Novimmune Sa Reciprocally masked antibody-cytokine fusion proteins and methods of use thereof
CN117917438A (zh) * 2022-10-21 2024-04-23 北京诺诚健华医药科技有限公司 抗体融合蛋白及其制备和应用
WO2024119193A2 (en) * 2022-12-02 2024-06-06 AskGene Pharma, Inc. Mutant il-2 polypeptides and il-2 prodrugs
US20240376170A1 (en) 2023-01-11 2024-11-14 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
GB202301945D0 (en) 2023-02-10 2023-03-29 Mount Natalie Novel immunoconjugates
EP4450093A1 (en) 2023-04-17 2024-10-23 Synaffix B.V. Cleavable immune cell engagers
WO2024218164A1 (en) 2023-04-17 2024-10-24 Synaffix B.V. Stable 4-isoxazoline conjugates
WO2024261212A1 (en) * 2023-06-22 2024-12-26 Aarhus Universitet Multi-specific proteinaceous prodrug constructs
WO2025024658A1 (en) * 2023-07-27 2025-01-30 Binacea Pharma, Inc. Mutant il-2 fusions with immune cell specific binding proteins and methods of use thereof
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
WO2025122660A1 (en) * 2023-12-04 2025-06-12 AskGene Pharma, Inc. Chimeric proteins comprising masked il-2
WO2025122614A1 (en) * 2023-12-05 2025-06-12 Regeneron Pharmaceuticals, Inc. Il18 receptor agonists and methods of use thereof
WO2025162454A1 (zh) * 2024-02-02 2025-08-07 北京昌平实验室 双特异性抗体和细胞因子融合蛋白及其应用
WO2025165594A1 (en) * 2024-02-02 2025-08-07 Staidson Biopharma Inc. Anti-pd-l1 and il-15 prodrug bifunctional protein and uses thereof
WO2025201242A1 (en) * 2024-03-25 2025-10-02 Tavotek Biotherapeutics (Hong Kong) Limited Antibodies targeting fap and lrrc15 and fusion proteins targeting hyaluronan and uses thereof
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains
WO2026083295A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
CN119639683A (zh) * 2024-12-21 2025-03-18 浙江大学绍兴研究院 一种表达il-15靶向b7h3的嵌合抗原受体-t细胞及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
DE10045592A1 (de) 2000-09-15 2002-03-28 Klaus Pfizenmaier Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie
WO2003015697A2 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
US8809504B2 (en) 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
US20060234205A1 (en) * 2004-03-05 2006-10-19 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
ES2368868T3 (es) 2006-09-20 2011-11-23 Mt-Biomethan Gmbh Procedimiento y dispositivo para la separación de metano y dióxido de carbono de biogás.
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
AU2010206840B2 (en) 2009-01-21 2015-02-05 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
MX2011010166A (es) * 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
WO2012065086A1 (en) 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
SG192673A1 (en) 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
PE20141017A1 (es) 2011-03-02 2014-08-25 Roche Glycart Ag Anticuerpos del cea
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
EP2961773B1 (en) * 2013-02-26 2019-03-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
WO2015066279A2 (en) * 2013-10-30 2015-05-07 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
RU2689717C2 (ru) * 2014-01-08 2019-05-28 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Гетеродимерный белок il-15 и его применения
WO2016023040A1 (en) * 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
AU2015301936B2 (en) * 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
CN104403004B (zh) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
IL299616A (en) * 2016-01-08 2023-03-01 Univ California Conditionally active heterodimeric polypeptides and methods of using them
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины

Similar Documents

Publication Publication Date Title
JP2021515599A5 (enExample)
WO2019173832A4 (en) Cytokine prodrugs
JP2021530243A5 (enExample)
CN114401997B (zh) 细胞因子前药和双前药
Forsberg et al. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen
JP2022169543A (ja) 改善された養子ｔ細胞療法
JP6700325B2 (ja) 抗原をトランスフェクトされたｔ細胞を伴う二重特異性抗体分子及び医薬におけるそれらの使用
JP2022545439A5 (enExample)
Stork et al. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G
JP3860398B2 (ja) サイトカインの免疫複合体
JP2022536898A (ja) 新規ｉｌ－１５プロドラッグおよびその使用方法
JP2022542886A (ja) プロテアーゼ活性化治療剤を含む組成物および方法
JP2022512043A5 (enExample)
JP2022545439A (ja) 新規ｉｌ－２１プロドラッグおよびその使用方法
JP2021521822A5 (enExample)
JP2023123649A5 (enExample)
US20240218065A1 (en) Multispecific antigen-binding protein and use thereof
CN115232209A (zh) 靶向gprc5d的抗体及其用途
US20070237771A1 (en) Multicomponent conjugates which bind to target molecules and stimulate T cell lysis
EP4121458A1 (en) Guidance and navigation control (gnc) antibody-like proteins and methods of making and using thereof
CN117157312A (zh) 蛋白酶活化的多肽
TWI869544B (zh) 雙特異性結合分子
JP2023523083A5 (enExample)
Puca et al. The targeted delivery of interleukin-12 to the carcinoembryonic antigen increases the intratumoral density of NK and CD8+ T cell in an immunocompetent mouse model of colorectal cancer
CN115154598A (zh) 一种抗pd-1/vegf双特异性抗体液体制剂